Frontier Health

Belkins
Frontier Health's vision is to establish and provide accessible, high quality care. Frontier Health, a 501(c) 3, is the area’s leading provider of mental health, substance abuse, co-occurring, developmental and intellectual disabilities, recovery and vocational rehabilitation services for adults, children and youth at 64 sites in Northeast Tennessee and Southwest Virginia. Frontier Health's mission is to provide quality services that encourage people to achieve their full potential. To provide those services, Frontier’s 1,005 employees traveled 1.74 million miles during FY 2014-15 in a 12,000-square-mile coverage area for 48,862 individuals. Frontier Health also provides an adult residential treatment for addiction and/or co-occurring disorders, services for individuals who are deaf or hard of hearing, domestic violence victims, youth in crisis, runaways, foster care and adoption services.

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us

Events

Related News

MEDICAL

MERCK ENTERS INTO SUPPLY AGREEMENT WITH U.S. GOVERNMENT TO MANUFACTURE AND INITIAL DISTRIBUTION OF INVESTIGATIONAL BIOLOGICAL THERAPEUTIC

Merck | December 28, 2020

news image

Merck (NYSE: MRK), known as MSD outside the United States and Canada, today declared it has gone into a agreement with the United States Government to help the turn of events, assembling and introductory dispersion of an investigational biological therapeutic (CD24Fc, to be named MK-7110) upon endorsement or Emergency Use Authorization (EUA) from the U.S. Food and Drug Administration (FDA). Merck acquired MK-7110 through the securing of OncoImmune, a privately held, clinical-stage biopharmaceuti...

Read More

INDUSTRIAL IMPACT

LEGEND BIOTECH ANNOUNCES EXTENSION OF PDUFA DATE FOR CILTA-CEL

Cilta-cel | November 01, 2021

news image

Legend Biotech Corporation (Legend Biotech), a global, clinical-stage biotechnology company developing and manufacturing novel therapies, today announced that the U.S. Food and Drug Administration has extended the Prescription Drug User Fee Act (PDUFA) target date for ciltacabtagene autoleucel (cilta-cel) to February 28, 2022. Cilta-cel is a BCMA-directed chimeric antigen receptor T cell (CAR-T) therapy being investigated for the treatment of adults with relapsed and/or refractory multiple myelo...

Read More

PROVENTION BIO AND VACTECH ANNOUNCE PUBLICATION OF PROOF-OF-CONCEPT DATA FOR COXSACKIEVIRUS B VACCINE

Provention Bio, Inc. | May 19, 2020

news image

The preclinical prototype vaccine is well-tolerated and provides strong protection against coxsackievirus B infections and diabetes in relevant animal models. Results provide a solid scientific basis for human trials with Provention's PRV-101 vaccine. Read More

CELL AND GENE THERAPY

Y-BIOLOGICS AND PIERRE FABRE ANNOUNCES STRATEGIC PARTNERSHIP IN THE FIELD OF IMMUNO-ONCOLOGY RESEARCH

Y-Biologics | November 23, 2020

news image

The South Korean biotech organization Y-Biologics and the French pharmaceutical group Pierre Fabre have declared their arrangements to frame a key association in the field of immuno-oncology research. The choice has been recognized through a letter of aim endorsed by the two players and will be affirmed in the coming a very long time through an itemized arrangement. The joint effort is set to run for a very long time, with the chance of a two-year expansion. Y-Biologics, which spe...

Read More
news image

MEDICAL

MERCK ENTERS INTO SUPPLY AGREEMENT WITH U.S. GOVERNMENT TO MANUFACTURE AND INITIAL DISTRIBUTION OF INVESTIGATIONAL BIOLOGICAL THERAPEUTIC

Merck | December 28, 2020

Merck (NYSE: MRK), known as MSD outside the United States and Canada, today declared it has gone into a agreement with the United States Government to help the turn of events, assembling and introductory dispersion of an investigational biological therapeutic (CD24Fc, to be named MK-7110) upon endorsement or Emergency Use Authorization (EUA) from the U.S. Food and Drug Administration (FDA). Merck acquired MK-7110 through the securing of OncoImmune, a privately held, clinical-stage biopharmaceuti...

Read More
news image

INDUSTRIAL IMPACT

LEGEND BIOTECH ANNOUNCES EXTENSION OF PDUFA DATE FOR CILTA-CEL

Cilta-cel | November 01, 2021

Legend Biotech Corporation (Legend Biotech), a global, clinical-stage biotechnology company developing and manufacturing novel therapies, today announced that the U.S. Food and Drug Administration has extended the Prescription Drug User Fee Act (PDUFA) target date for ciltacabtagene autoleucel (cilta-cel) to February 28, 2022. Cilta-cel is a BCMA-directed chimeric antigen receptor T cell (CAR-T) therapy being investigated for the treatment of adults with relapsed and/or refractory multiple myelo...

Read More
news image

PROVENTION BIO AND VACTECH ANNOUNCE PUBLICATION OF PROOF-OF-CONCEPT DATA FOR COXSACKIEVIRUS B VACCINE

Provention Bio, Inc. | May 19, 2020

The preclinical prototype vaccine is well-tolerated and provides strong protection against coxsackievirus B infections and diabetes in relevant animal models. Results provide a solid scientific basis for human trials with Provention's PRV-101 vaccine. Read More

news image

CELL AND GENE THERAPY

Y-BIOLOGICS AND PIERRE FABRE ANNOUNCES STRATEGIC PARTNERSHIP IN THE FIELD OF IMMUNO-ONCOLOGY RESEARCH

Y-Biologics | November 23, 2020

The South Korean biotech organization Y-Biologics and the French pharmaceutical group Pierre Fabre have declared their arrangements to frame a key association in the field of immuno-oncology research. The choice has been recognized through a letter of aim endorsed by the two players and will be affirmed in the coming a very long time through an itemized arrangement. The joint effort is set to run for a very long time, with the chance of a two-year expansion. Y-Biologics, which spe...

Read More

Resources

Events

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us